Pharma Focus Asia

ICON Signs New Service Agreement With Pfizer

Saturday, April 04, 2020

ICON plc, a leading global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc.. Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.

The agreement builds on the companies' existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.

Steve Cutler, ICON's CEO, commented: "The further progression of ICON’s long-standing relationship with Pfizer is clear recognition of our capabilities and expertise in partnering with Pfizer on their drug development and commercialisation efforts. We look forward to continuing our strong relationship with Pfizer to help advance their pipeline and deliver continued innovation in the drug development process."

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024